Df. Braus et al., Antipsychotic drug effects on motor activation measured by functional magnetic resonance imaging in schizophrenic patients, SCHIZOPHR R, 39(1), 1999, pp. 19-29
Brain function and laterality in schizophrenia were investigated by means o
f a simple motor task with a self-generated left-hand sequential finger opp
osition (SFO) using a whole-brain high-speed (100 ms per slice) functional
imaging technique. Neuroleptic-naive, acutely ill schizophrenic patients we
re compared to schizophrenic patients under stable neuroleptic medication a
nd matched controls. The goal was to evaluate both the motor function in fi
rst-episode patients and possible effects of different neuroleptic treatmen
ts on functional MRI results. Forty patients satisfying ICD 10 criteria (F2
0.x) for schizophrenia and sex- and age-matched healthy volunteers particip
ated in this study. All subjects underwent fMRI examinations on a conventio
nal 1.5 T MR unit. The primary sensorimotor cortex and the high-order suppl
ementary motor area (SMA) were evaluated. There was a close similarity in t
he activation of the primary and high-order (SMA) sensorimotor areas betwee
n first-episode schizophrenic patients and controls. In contrast, a signifi
cant reduction in the overall blood oxygen level dependent (BOLD) response
was seen in sensorimotor cortices (contra- and ipsilateral) in schizophreni
c patients under stable medication with typical neuroleptics. This effect w
as not present in patients treated with atypical antipsychotics. Both antip
sychotic treatments, however, led to a significant reduction in activation
of the SMA region compared to controls and neuroleptic-naive subjects. Thus
, the present study provides no evidence for the localized involvement of t
he primary motor cortex or the SMA as a relatively stable vulnerability mar
ker in schizophrenia. There is, however, strong evidence that neuroleptics
themselves influence fMRI activation patterns and that there are major diff
erences between typical neuroleptics and atypical antipsychotics. (C) 1999
Elsevier Science B.V. All rights reserved.